RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1260
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals and raises the price target from $1252 to $1260.
October 04, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating on Regeneron Pharmaceuticals and increased the price target from $1252 to $1260, indicating confidence in the company's future performance.
The increase in price target from $1252 to $1260 by RBC Capital suggests a positive outlook on Regeneron's future performance. The Outperform rating indicates that the analyst expects the stock to perform better than the market average, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100